BK7508 Pharmaceutical Companies
Closed 01-10 16:00:00 AEDT
947.94
-6.27
-0.66%
High
957.75
Low
945.33
Vol
38.50M
Open
956.34
D1 Closing
954.21
Amplitude
1.30%
Mkt Cap
0.00
Tradable Cap
0.00
Total Shares
0.00
T/O
81.09M
T/O Rate
--
Tradable Shares
0.00
P/B
--
ROE
--
EPS
0.00
52wk High
--
52wk Low
--
P/E
--
Dividend
--
Div.Yield
--
ROA
--
Time
5D
D
W
M
News
New Post(s)
Profile
Sparc fires up following three-way hydrogen tie-in
The Sydney Morning Herald · 14:09
Sparc fires up following three-way hydrogen tie-in
Imugene Receives Nearly AU$12 Million R&D Tax Refund
MT Newswires Live · 12:19
Imugene Receives Nearly AU$12 Million R&D Tax Refund
3 ASX small-cap shares that ripped 295% to 900% in 2024
MotleyFool · 12:08
3 ASX small-cap shares that ripped 295% to 900% in 2024
The only Australian stocks I own at the start of 2025
MotleyFool · 11:56
The only Australian stocks I own at the start of 2025
3 ASX All Ords shares leading the charge in 2025
MotleyFool · 10:55
3 ASX All Ords shares leading the charge in 2025
3 ASX 200 healthcare stocks with 'strong return potential' in 2025
MotleyFool · 10:28
3 ASX 200 healthcare stocks with 'strong return potential' in 2025
Mesoblast Says JPMorgan Chase Reduces Shareholding
MT Newswires Live · 10:21
Mesoblast Says JPMorgan Chase Reduces Shareholding
HotCopper users flock to make sense of darling Mesoblast’s ‘proposed financing’
The Market Herald · 09:44
HotCopper users flock to make sense of darling Mesoblast’s ‘proposed financing’
Why are Mesoblast shares in a trading halt?
MotleyFool · 08:44
Why are Mesoblast shares in a trading halt?
Mesoblast Requests Trading Halt
MT Newswires Live · 07:39
Mesoblast Requests Trading Halt
BRIEF-Mesoblast Ltd Seeks Trading Halt
Reuters · 06:58
BRIEF-Mesoblast Ltd Seeks Trading Halt
How to try and turn a small ASX share portfolio into $200k, starting in 2025
MotleyFool · 05:40
How to try and turn a small ASX share portfolio into $200k, starting in 2025
The next big thing: 10 industries and 17 stocks poised to break out in 2025
LiveWire · 04:00
The next big thing: 10 industries and 17 stocks poised to break out in 2025
3 no-brainer ASX 200 blue chip stocks to buy this month
MotleyFool · 01:11
3 no-brainer ASX 200 blue chip stocks to buy this month
Dimerix Exclusive Japan Licensing Deal 'Positive Suprise,' Euroz Hartleys Says
MT Newswires Live · 01-09 13:41
Dimerix Exclusive Japan Licensing Deal 'Positive Suprise,' Euroz Hartleys Says
Why AVITA Medical, Lovisa, Star, and Westgold shares are sinking today
MotleyFool · 01-09 09:26
Why AVITA Medical, Lovisa, Star, and Westgold shares are sinking today
5 Australian stocks to hold for the next decade
MotleyFool · 01-09 06:59
5 Australian stocks to hold for the next decade
CSL stock: Buy, hold, or sell in 2025?
MotleyFool · 01-09 05:59
CSL stock: Buy, hold, or sell in 2025?
16 ASX shares that doubled in value last year
MotleyFool · 01-09 04:00
16 ASX shares that doubled in value last year
BUZZ-Australia-listed shares of AVITA Medical slump on forecast cut
Reuters · 01-08 12:34
BUZZ-Australia-listed shares of AVITA Medical slump on forecast cut
Load more
Introduction
Company Name.
BK7508
Affiliated Markets:
Listing Date:
--
Main Business:
Issue price:
--
{"stockData":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":947.9392,"timestamp":1736485199743,"preClose":954.2061,"halted":0,"volume":38504181,"delay":0,"changeRate":-0.006568,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-6.266907,"latestTime":"01-10 16:00:00 AEDT","open":956.3371,"high":957.75323,"low":945.32574,"amount":81092781,"amplitude":0.013024,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1736722800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1736463600000,1736485200000]],"turnoverRate":0.001047,"increases":13,"decrements":11,"flats":20,"marketCap":150911655022.5,"floatMarketCap":147190125928.75},"requestUrl":"/m/hq/s/BK7508","defaultTab":"news","newsList":[{"id":"2502839668","title":"Sparc fires up following three-way hydrogen tie-in","url":"https://stock-news.laohu8.com/highlight/detail?id=2502839668","media":"The Sydney Morning Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502839668?lang=en_us&edition=fundamental","pubTime":"2025-01-10 14:09","pubTimestamp":1736489340,"startTime":"0","endTime":"0","summary":"This week the market again encountered a diverse mix of high-flying winners, with those finding favour on the market comprising a new-age hydrogen tech developer, an immune-related disorder biopharma firm, a mining company growing its scandium critical mineral resource and a drug developer joining forces with a Japanese pharmaceutical firm to fight kidney disease.This week’s Bulls N’ Bears ASX Runner of the Week is…","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.smh.com.au/business/companies/sparc-fires-up-following-three-way-hydrogen-tie-in-20250110-p5l3fv.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smh_stock","symbols":["BK7501","BK7504","DXB.AU","BK7095","BK7067","RGT.AU","AUZ.AU","BK7036","BK7096","SPN.AU","BK7508"],"gpt_icon":0},{"id":"2502000806","title":"Imugene Receives Nearly AU$12 Million R&D Tax Refund","url":"https://stock-news.laohu8.com/highlight/detail?id=2502000806","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502000806?lang=en_us&edition=fundamental","pubTime":"2025-01-10 12:19","pubTimestamp":1736482763,"startTime":"0","endTime":"0","summary":"Imugene received a tax refund of AU$11.7 million for the fiscal year ended June 30, 2023, from the Australian federal government's research and development tax incentive scheme, according to a Friday filing with the Australian bourse.The scheme encourages Australian firms to conduct research and development activities by providing a refund for eligible expenditures.Funds from the rebate will be used by the immunotherapy firm to advance the development of products in the pipeline, the filing said.The company's shares fell past 2% in recent Friday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","BK7067","XJO.AU","IMU.AU","XAO.AU","BK7508"],"gpt_icon":0},{"id":"2502883159","title":"3 ASX small-cap shares that ripped 295% to 900% in 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2502883159","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502883159?lang=en_us&edition=fundamental","pubTime":"2025-01-10 12:08","pubTimestamp":1736482139,"startTime":"0","endTime":"0","summary":"ASX small-cap shares put in a solid performance last year, with the S&P/ASX Small Ordinaries Index (ASX: XSO) rising 5.54% and delivering total returns, including dividends, of 8.36%. By comparison, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/10/3-asx-small-cap-shares-that-ripped-295-to-900-in-2024/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["IPX.AU","ZIP.AU","BK7093","PNI.AU","BK7084","SPR.AU","CU6.AU","SIG.AU","360.AU","MSB.AU","BK7508","BK7104","BK7015","XJO.AU","BK7103","NXL.AU","BK7501","BK7062","BK7116","BK7096","XKO.AU","BK7016","BK7067","XAO.AU","CDA.AU","SLC.AU"],"gpt_icon":0},{"id":"2502007761","title":"The only Australian stocks I own at the start of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2502007761","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502007761?lang=en_us&edition=fundamental","pubTime":"2025-01-10 11:56","pubTimestamp":1736481375,"startTime":"0","endTime":"0","summary":"CSL Ltd and Wesfarmers Ltd can be considered core holdings, though. Both companies are amongst the highest-calibre businesses on the ASX, in my view. I love CSL's global presence in the healthcare space, as well as its tight business model and future-focused management team. With Wesfarmers, I appreciate the exposure to some of Australia's best retailers in Bunnings and OfficeWorks. As we","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/10/the-only-australian-stocks-i-own-at-the-start-of-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7145","NEM.AU","XJO.AU","ADH.AU","BK7141","A2M.AU","EDV.AU","LIC.AU","NAB.AU","BK7040","BK7508","WOW.AU","SOL.AU","BK7107","BK7049","BK7083","XAO.AU","KGN.AU","MFF.AU","BK7041","BK7135","WBC.AU","BK7067","TLS.AU","XKO.AU","WES.AU","PL8.AU","BK7505","BK7153","CSL.AU","BK7042","BK7501","BK7105","BK7511","BK7104"],"gpt_icon":0},{"id":"2502009293","title":"3 ASX All Ords shares leading the charge in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2502009293","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502009293?lang=en_us&edition=fundamental","pubTime":"2025-01-10 10:55","pubTimestamp":1736477701,"startTime":"0","endTime":"0","summary":"Although under pressure today, the All Ordinaries Index is up 1.3% so far in 2025, with three ASX All Ords shares racing ahead of those gains. At market close yesterday, these three companies were leading the charge higher in the nascent new year. You'll also notice a decided trend in the sector they operate in. Which soaring ASX All Ords shares are we talking about?) The EBR Systems share price closed out 2024 at $1.025. In Friday afternoon trade, shares are changing hands for $1.40 apiece. That sees this ASX All Ords stock up 36.6% already in the new year. On Monday, the company, which is developing the world's only wireless cardiac pacing device for heart failure , reported that the US Food and Drug Administration had scheduled the manufacturing Pre-Approval Inspection to commence on 14 January. \"This significant","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/10/3-asx-all-ords-shares-leading-the-charge-in-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7007","EBR.AU","PAI","PAI.AU","XJO.AU","XKO.AU","BK7067","XAO.AU","CYC.AU","IMU.AU","BK7508"],"gpt_icon":0},{"id":"2502009217","title":"3 ASX 200 healthcare stocks with 'strong return potential' in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2502009217","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502009217?lang=en_us&edition=fundamental","pubTime":"2025-01-10 10:28","pubTimestamp":1736476121,"startTime":"0","endTime":"0","summary":"Three S&P/ASX 200 Index healthcare stocks are well placed to benefit from growing demand for their services in 2025. That's according to Piers Bolger, chief investment officer of Infinity Asset Management. Commenting on the investment outlook for 2025, Bolger said, \"Overall, the investment outlook for 2025 is positive but cautious.\" He added: Lower interest rates and strong equity dynamics present opportunities but risks like geopolitical tensions and uneven global growth require careful navigation. A flexible, growth-focused approach will be essential to manage challenges and seize opportunities. Citing high valuations and declining earnings, Bolger said he's cautious on ASX 200 bank stocks. But he has a positive outlook for the healthcare sector. ASX 200 healthcare stocks facing demand growth in 2025 Drilling into three specific ASX 200 healthcare stocks he's bullish on, Bolger named global pathology provider Sonic Healthcare Ltd , biotech giant CSL Ltd , and sleep disorder treatme","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/10/3-asx-200-healthcare-stocks-with-strong-return-potential-in-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7501","BK7007","CSL.AU","BK7067","BK7124","SHL.AU","BK7511","RMD.AU","XJO.AU","BK7508"],"gpt_icon":0},{"id":"2502005712","title":"Mesoblast Says JPMorgan Chase Reduces Shareholding","url":"https://stock-news.laohu8.com/highlight/detail?id=2502005712","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502005712?lang=en_us&edition=fundamental","pubTime":"2025-01-10 10:21","pubTimestamp":1736475703,"startTime":"0","endTime":"0","summary":"Mesoblast said JPMorgan Chase & Co and its affiliates reduced their voting power in the company to 7.16% from 8.34% on Tuesday, according to a Friday filing with the Australian bourse.The financial services firm and its affiliates reduced its shareholdings in the biotechnology firm to 82,2 million shares from 95.3 million shares as of the last notice dated Dec. 19, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MSB.AU","BK7508","MESO","BK7067","BK7501","JPM","BK4139"],"gpt_icon":0},{"id":"2502100322","title":"HotCopper users flock to make sense of darling Mesoblast’s ‘proposed financing’","url":"https://stock-news.laohu8.com/highlight/detail?id=2502100322","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502100322?lang=en_us&edition=fundamental","pubTime":"2025-01-10 09:44","pubTimestamp":1736473440,"startTime":"0","endTime":"0","summary":"If you’ve been paying attention, you know Mesoblast is currently something of an Australian market darling.Just take a look at its recent run. One-year returns are currently up +868%, borne largely from the US FDA’s decision to approve Mesoblast’s drug Ryoncil in mid-December.For those who remember Droneshield’s stellar run through the first half of last year , it’s safe to say Mesoblast took the crown as market darling right before the clinching point of 2024.Mesoblast has since popped to a $3 billion-plus market cap.Maybe not quite WA1 Resources tier growth, but still impressive enough in what was a fairly dry 2024 when it came to stock picking.Boring stocks like Coles , CBA , and Woolworths will always be advisable but what the trading community really wants is to behave like smart money.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified fi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/hotcopper-users-flock-to-make-sense-of-darling-mesoblasts-proposed-financing-2025-01-10/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["CBA.AU","BK7040","BK7511","BK7508","WOW.AU","BK4139","BK7153","COL.AU","HVN.AU","MSB.AU","BK7041","BK7095","BK7082","BK7135","MESO","WA1.AU","BK7501","BK7067"],"gpt_icon":0},{"id":"2502005926","title":"Why are Mesoblast shares in a trading halt?","url":"https://stock-news.laohu8.com/highlight/detail?id=2502005926","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502005926?lang=en_us&edition=fundamental","pubTime":"2025-01-10 08:44","pubTimestamp":1736469874,"startTime":"0","endTime":"0","summary":"The Mesoblast Ltd share price is going nowhere after the company requested a trading haltthis morning. Mesoblast requested that the trading halt remain in place ahead of an announcement about \"a proposed financing\". The company revealed no other details in its formal request. The ASX confirmed Mesoblast shares would remain frozen until the earlier of the announcement or the start of trading next Tuesday. Mesoblast share price on hold ahead of financing news Mesoblast was the number one S&P/ASX All Ordinaries Index share for price growth in 2024. The ASX biotechshare rose by an astounding 900% to finish the year at $3.10 apiece on 31 December. Already in the new year, Mesoblast shares have hit a four-year high of $3.37. They closed at $2.81 apiece yesterday. What powered the 900% rise in Mesoblast shares last year?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/10/why-are-mesoblast-shares-in-a-trading-halt/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["MSC","BK4139","BK7501","XAO.AU","BK7508","BK4575","BK7067","BK4150","MSB.AU","MESO"],"gpt_icon":0},{"id":"2502507620","title":"Mesoblast Requests Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2502507620","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502507620?lang=en_us&edition=fundamental","pubTime":"2025-01-10 07:39","pubTimestamp":1736465963,"startTime":"0","endTime":"0","summary":"Mesoblast requested that its securities be placed in trading halt until an announcement related to a proposed financing is made, according to a Friday filing with the Australian bourse.The trading halt will remain in place until the start of trading on Jan. 14 or when the company makes the financing announcement, the filing said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK4139","XAO.AU","XJO.AU","MSB.AU","XKO.AU","MESO","BK7501","BK7508"],"gpt_icon":0},{"id":"2502807374","title":"BRIEF-Mesoblast Ltd Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2502807374","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502807374?lang=en_us&edition=fundamental","pubTime":"2025-01-10 06:58","pubTimestamp":1736463537,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Ltd Seeks Trading HaltJan 10 (Reuters) - Mesoblast Ltd MSB.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON PROPOSED FINANCINGFurther company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250109:nFWN3O50SC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7501","BK4139","BK7067","MSB.AU","MESO"],"gpt_icon":0},{"id":"2502020326","title":"How to try and turn a small ASX share portfolio into $200k, starting in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2502020326","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502020326?lang=en_us&edition=fundamental","pubTime":"2025-01-10 05:40","pubTimestamp":1736458809,"startTime":"0","endTime":"0","summary":"As I said up top, if you're starting with a small stake, you're highly unlikely to grow your ASX share portfolio to $200,000 in 2025 alone. But if you can invest $800 a month into the market, at 9% annual returns, starting now you should hit your goal of $200,000 in about 12 years.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/10/how-to-try-and-turn-a-small-asx-share-portfolio-into-200k-starting-in-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4585","BK7095","BK4550","BK7507","VAS.AU","XJO.AU","BHP.AU","BK4588","BK7093","QAN.AU","BK7501","ETF.AU","BK7508","BK7511","BK7135","BK7030","ZIP.AU","XKO.AU","CBA.AU","FDN","BK7067","CSL.AU"],"gpt_icon":0},{"id":"2502026684","title":"The next big thing: 10 industries and 17 stocks poised to break out in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2502026684","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502026684?lang=en_us&edition=fundamental","pubTime":"2025-01-10 04:00","pubTimestamp":1736452814,"startTime":"0","endTime":"0","summary":"Move over big tech, there are more opportunities in town.After starting 2024 with earnings downgrades for a range of sectors and a slowdown in consumer spending, it was a bumper year for a number of sectors. Consumer discretionary was one surprise winner, with well-positioned brands like JB Hi-Fi and Nick Scali taking charge. Australian banks facing into a tougher environment continued to outperform, as did the financial sector on the whole, with insurers taking advantage of higher premiums. Biotech also started to surge, as falling rates outside of Australia and a number of successful clinical trials bolstered the sector.Of course, the big tech companies continued to dominate and push markets to record highs - it's hard to ignore the extraordinary growth in the likes of Nvidia for example, but it's worth noting the pace of the growth seems to be moderating somewhat.With valuations at a premium in the tech sector, there are a range of other areas where fund managers are hunting for big","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/the-next-big-thing-10-industries-and-17-stocks-poised-to-break-out-in-2025","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/the-next-big-thing-10-industries-and-17-stocks-poised-to-break-out-in-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK4533","CCJ","BK7110","OPT.AU","LU2249611893.SGD","HLS.AU","DSE.AU","LU2357125470.USD","LU0823414478.USD","BK7508","ASB.AU","BK4022","XKO.AU","XAO.AU","BOE.AU","XJO.AU","ODFL","BK7160","BK4591","BK4202","BK7016","LU0823414551.USD","BK7124","AS","AFG.AU","BK4232","SHL.AU","IE0008368304.USD","BK7083","CSC.AU","BK4156","BK7067","LU2506951792.HKD","BK7509","BK4504","ACL.AU","BK4585","BK7123","BK4566","BK7501","BK4588","GTK.AU","BK7115","LU2294711713.HKD","BK7503"],"gpt_icon":0},{"id":"2502047723","title":"3 no-brainer ASX 200 blue chip stocks to buy this month","url":"https://stock-news.laohu8.com/highlight/detail?id=2502047723","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502047723?lang=en_us&edition=fundamental","pubTime":"2025-01-10 01:11","pubTimestamp":1736442660,"startTime":"0","endTime":"0","summary":"If you're aiming to build a strong investment portfolio, then it is usually a good idea to include a few blue chipsin there. But which blue chip ASX 200 stocks could be buys in January?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/10/3-no-brainer-asx-200-blue-chip-stocks-to-buy-this-month/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7508","BK7501","BK7043","WOW.AU","BK7067","BK7511","BK7040","BK7503","CSL.AU","NXT.AU"],"gpt_icon":0},{"id":"2502270057","title":"Dimerix Exclusive Japan Licensing Deal 'Positive Suprise,' Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2502270057","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502270057?lang=en_us&edition=fundamental","pubTime":"2025-01-09 13:41","pubTimestamp":1736401282,"startTime":"0","endTime":"0","summary":"Dimerix's exclusive licensing agreement in Japan for its kidney disease drug candidate is a \"positive surprise,\" presenting additional value for the firm in the region, according to a Thursday note from Euroz Hartleys.Dimerix disclosed Tuesday that it entered into an exclusive development and license agreement worth a total of AU$107 million with Fuso Pharmaceutical Industries to develop and commercialize its drug candidate, DMX-200, to treat focal segmental glomerulosclerosis in Japan.The Fuso licensing deal, Dimerix's third such deal, validates the ability of the firm's management to license across multiple territories, including in key markets like the US and Mainland China.Collectively, these licensing deals provide the company up to AU$458 million in upfront and potential milestone payments, as well as royalties on net sales.Importantly, Fuso, as a leading firm in the dialysis and renal/urology field, is well-positioned as an ideal partner for Dimerix in the region, the note sai","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FSGS","BK7067","DXB.AU","BK7501","BK7508"],"gpt_icon":0},{"id":"2502193031","title":"Why AVITA Medical, Lovisa, Star, and Westgold shares are sinking today","url":"https://stock-news.laohu8.com/highlight/detail?id=2502193031","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502193031?lang=en_us&edition=fundamental","pubTime":"2025-01-09 09:26","pubTimestamp":1736385990,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index(ASX: XJO) is out of form and dropping into the red on Thursday. In afternoon trade, the benchmark index is down 0.4% to 8,314.6 points. Four ASX shares that are falling more than ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/09/why-avita-medical-lovisa-star-and-westgold-shares-are-sinking-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7128","LOV.AU","BK7506","BK7067","BK7078","BK7508","SGR.AU","XJO.AU","BK7104","AVH.AU","WGX.AU"],"gpt_icon":0},{"id":"2502082887","title":"5 Australian stocks to hold for the next decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2502082887","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502082887?lang=en_us&edition=fundamental","pubTime":"2025-01-09 06:59","pubTimestamp":1736377197,"startTime":"0","endTime":"0","summary":"I think buy and hold investing is one of the best ways to grow your wealth.That's because it allows investors to benefit from the power of compounding.This is what happens when you earn returns on top of returns. It essentially supercharges your wealth creation.But not all Australian stocks are necessarily good options for buy and hold investing.So, let's narrow things down and pick five buy-rated stocks that could be just the ticket for investors. They are as follows:. The first Australian stock that could be a great buy and hold option for investors is CSL. It is the biotechnology giant responsible for the CSL Behring, CSL Vifor, and CSL Seqirus businesses.Bell Potter thinks that the positive outlook for the CSL Behring business makes it a great long-term option. It recently said:. In our view the stock looks undervalued on a PE ratio 18%/8% below 5yr/10yr historical averages and is set for double-digit earnings growth driven by the core Behring division.Its analysts feel that the lo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/09/5-australian-stocks-to-hold-for-the-next-decade/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["RMD.AU","BK4127","IE0004091025.USD","XJO.AU","BK4516","IE0034235188.USD","BK7508","BK7503","LU2237438978.USD","LU2237443382.USD","BK7067","LU2237443622.USD","XRO.AU","LU2237443465.HKD","LU2237443895.HKD","BK7007","IE00BSNM7G36.USD","BK4550","XKO.AU","WTC.AU","BK7104","IE0002270589.USD","BK4588","BK7043","LU1791807156.HKD","LU0106831901.USD","LU2237443978.SGD","TAM.AU","BK4504","LU1668664300.SGD","IE00B19Z3581.USD","BK7511","BK7016","IE00B19Z3B42.SGD","BK4552","NXT.AU","IE0004086264.USD","BK4585","CSL.AU","BK4533","LU2237443549.SGD","XAO.AU","BK7501","IE00BFXG1179.USD"],"gpt_icon":0},{"id":"2502817820","title":"CSL stock: Buy, hold, or sell in 2025?","url":"https://stock-news.laohu8.com/highlight/detail?id=2502817820","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502817820?lang=en_us&edition=fundamental","pubTime":"2025-01-09 05:59","pubTimestamp":1736373591,"startTime":"0","endTime":"0","summary":"CSL Ltd stock had an underwhelming year in 2024. During the 12 months, the biotechnology giant's shares traded relatively flat and underperformed the market. While this is disappointing, has it created a buying opportunity for investors in 2025?Let's find out. CSL stock: Buy, hold, or sell in 2025?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/09/csl-stock-buy-hold-or-sell-in-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["CSL.AU","SGXZ23171101.USD","SG9999004303.SGD","LU0728928796.USD","BK4086","BK7508","CSL","LU1169589451.USD","BK7501","BK7067","BK7511","LU1169590202.USD"],"gpt_icon":0},{"id":"2502088116","title":"16 ASX shares that doubled in value last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2502088116","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502088116?lang=en_us&edition=fundamental","pubTime":"2025-01-09 04:00","pubTimestamp":1736366400,"startTime":"0","endTime":"0","summary":"S&P/ASX All Ordinaries Index (ASX: XAO) shares rose by 7.55% last year and delivered total gross returns, including dividends, of 11.44%. The index closed the year at 8,420.5 points. In comparison, t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/09/16-asx-shares-that-doubled-in-value-last-year/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7116","CU6.AU","IPX.AU","PME.AU","BK7062","SPR.AU","MSB.AU","BK7084","BK4023","BK7061","XAO.AU","CAT.AU","BK7508","PNI.AU","BK7016","360.AU","BK7067","BK7503","BK7104","BK7501","NXL.AU","BK7103","BK7096","TNE.AU","BK7015","BK7093","ZIP.AU","TLX.AU","SIG.AU","BK7094","OBM.AU","APX.AU","XJO.AU","SLC.AU","LIF"],"gpt_icon":0},{"id":"2501804799","title":"BUZZ-Australia-listed shares of AVITA Medical slump on forecast cut","url":"https://stock-news.laohu8.com/highlight/detail?id=2501804799","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501804799?lang=en_us&edition=fundamental","pubTime":"2025-01-08 12:34","pubTimestamp":1736310856,"startTime":"0","endTime":"0","summary":"* ASX-listed shares of AVITA Medical AVH.AX RCEL.O fall as much as 20.2% to A$3.470. ** Stock last down about 18.8%, set for deepest one-day decline since Oct 2023","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nL4N3O409O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","AVH.AU","RCEL","BK4139"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0032},{"period":"1month","weight":-0.0109},{"period":"3month","weight":0.0239},{"period":"6month","weight":0.056},{"period":"1year","weight":0.1607},{"period":"ytd","weight":0.0034}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"name":"BK7508","nameEN":"BK7508"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pharmaceutical Companies(BK7508),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pharmaceutical Companies(BK7508) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pharmaceutical Companies,BK7508,Pharmaceutical Companies股票,Pharmaceutical Companies股票老虎,Pharmaceutical Companies股票老虎国际,Pharmaceutical Companies行情,Pharmaceutical Companies股票行情,Pharmaceutical Companies股价,Pharmaceutical Companies股市,Pharmaceutical Companies股票价格,Pharmaceutical Companies股票交易,Pharmaceutical Companies股票购买,Pharmaceutical Companies股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pharmaceutical Companies(BK7508),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pharmaceutical Companies(BK7508) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}